Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)

American Journal of Cardiology

Volumn 94, Issue 7, 2004, Pages 926-929

  Rebeiz, Abdallah G ^a   Dery, Jean Pierre ^a   Tsiatis, Anastasios A ^b   O'Shea, J Conor ^c   Johnson, Brent A ^b   Hellkamp, Anne S ^a   Pieper, Karen S ^h   Gilchrist, Ian C ^d   Slater, James ^e   Muhlestein, J Brent ^f   Joseph, Diane ^a   Kitt, Michael M ^g   Tcheng, James E ^a,h  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c Ireland   (United Kingdom)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f Latter Day Saints Hospital   (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO;

ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INFUSION; DRUG WITHDRAWAL; ELECTIVE SURGERY; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TIME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY DISEASE; CREATINE KINASE; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; HUMANS; INFUSIONS, INTRA-ARTERIAL; ISOENZYMES; MYOCARDIAL INFARCTION; NORTH AMERICA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 5344272476     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.06.030     Document Type: Article

References (13)

1. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet 356 2000 2037 2044
2. J.C. O'Shea, M. Madan, W.J. Cantor, C.M. Pacchiana, S. Greenberg, D.M. Joseph, M.M. Kitt, T.J. Lorenz, and J.E. Tcheng Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention Am Heart J 140 2000 834 839
3. B.A. Johnson, and A.A. Tsiatis Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored Biometrics 60 2004 315 320
4. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
5. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention Lancet 349 1997 1422 1428
6. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
7. The EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet 352 1998 87 92
8. J.E. Tcheng, S.G. Ellis, B.S. George, D.J. Kereiakes, N.S. Kleiman, J.D. Talley, A.L. Wang, H.F. Weisman, R.M. Califf, and E.J. Topol Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty Circulation 90 1994 1757 1764
9. R.A. Harrington, N.S. Kleiman, K. Kottke-Marchant, A.M. Lincoff, J.E. Tcheng, K.N. Sigmon, D. Joseph, G. Rios, K. Trainor, and D. Rose Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention Am J Cardiol 76 1995 1222 1227
10. D. Faulds, and E.M. Sorkin Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease Drugs 48 1994 583 598
11. N.S. Kleiman, A.E. Raizner, R. Jordan, A.L. Wang, D. Norton, K.F. Mace, A. Joshi, B.S. Coller, and H.F. Weisman Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implication for inhibition of the internal pool of GPIIb/IIIa receptors J Am Coll Cardiol 26 1995 1665 1671
12. R.E. Jordan, C.L. Wagner, M. Mascelli, G. Treacy, M.A. Nedelman, J.N. Woody, H.F. Weisman, and B.S. Coller Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans M.A. Horton Adhesion Receptors as Therapeutic Targets 1996 CRC Press Boca Raton, Florida 281 305
13. D.R. Phillips, W. Teng, A. Arfsten, L. Nannizzi-Alaimo, M.M. White, C. Longhurst, S.J. Shattil, A. Randolph, J.A. Jakubowski, and L.K. Jennings Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Circulation 96 1997 1488 1494